About Aptevo Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://aptevotherapeutics.com/
Frequently Asked Questions
What is the 52-week range for APVO?
The 52-week high is $35.64 and the 52-week low is $1.37.
What is the P/E ratio for APVO?
The P/E ratio data is currently unavailable.
What is the dividend yield for APVO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -201.49%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -222.55%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.51.
Analyst Recommendation Trends
Wall Street analyst consensus for APVO over the last few months:
Latest APVO News
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule, Enabling a Coordinated Approach to Recognizing Cancer, Activating Immune Cells and Addressing Tumor DefensesSEATTLE, WA / ACCESS Newswire / September 24, 2026 / Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-on
Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™
The trading volume of these stocks is deviating from the norm in today's session.
Unusual volume stocks are being observed in Friday's session.
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
The early RAINIER data showed a 79% CR/CRi rate in evaluable frontline TP53-mutated AML patients, comparing favorably with a published 41% composite remission benchmark for venetoclax plus azacitidine. Key Investor TakeawaysAptevo Therapeutics Inc.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies (NASDAQ:BIAF)
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment successSEATTLE, WA / ACCESS Newswire / September 3, 2026 / Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares increased by
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-06 | Lamothe Jeffrey G. | -961 | - | - |
| 2026-08-06 | Lamothe Jeffrey G. | +961 | - | - |
| 2026-08-06 | Kwon SoYoung | -638 | - | - |
| 2026-08-06 | Kwon SoYoung | +638 | - | - |
| 2026-08-06 | Huebner Dirk | -638 | - | - |
| 2026-08-06 | Huebner Dirk | -156 | $4.07 | $635 |
| 2026-08-06 | Huebner Dirk | +638 | - | - |
| 2026-08-06 | Grant Grady III | -400 | - | - |
| 2026-08-06 | Grant Grady III | +400 | - | - |
| 2026-08-06 | Kunz Barbara Lopez | -400 | - | - |
| 2026-08-06 | Kunz Barbara Lopez | +400 | - | - |
| 2026-08-06 | Niederhuber John | -400 | - | - |
| 2026-08-06 | Niederhuber John | +400 | - | - |
| 2026-08-06 | White Marvin L | -1,666 | - | - |
| 2026-08-06 | White Marvin L | -406 | $4.07 | $1,652 |
| 2026-08-06 | White Marvin L | +1,666 | - | - |
| 2026-08-06 | Taylor Daphne | -638 | - | - |
| 2026-08-06 | Taylor Daphne | +638 | - | - |
| 2026-08-06 | Abdun-Nabi Daniel | -400 | - | - |
| 2026-08-06 | Abdun-Nabi Daniel | +400 | - | - |
| 2026-08-06 | Harsanyi Zsolt | -400 | - | - |
| 2026-08-06 | Harsanyi Zsolt | +400 | - | - |
| 2026-07-17 | White Marvin L | -1 | - | - |
| 2026-07-17 | White Marvin L | +1 | - | - |
| 2025-11-10 | Grant Grady III | +13,513 | $1.49 | $20,134 |